Request Appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Intlekofer
Dr. Andrew Intlekofer is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 8 years. He is one of 502 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 50 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2015
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2011
Perelman School of Medicine at the University of PennsylvaniaClass of 2009
Certifications & Licensure
NY State Medical License 2011 - 2027
NJ State Medical License 2018 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsA patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.Danilo Fiore, Luca Vincenzo Cappelli, Liu Zhaoqi, Nikita Kotlov, Maria Sorokina
Cell Reports. Medicine. 2025-03-24 - 1 citationsPhase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2025-03-10 - Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, Michelle Okwali, Irem Isgor
Haematologica. 2025-02-01
Journal Articles
- Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface MutationsMartin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
Abstracts/Posters
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaAndrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Andrew M. Intlekofer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Grant Support
- Targeting isocitrate dehydrogenase mutations by enzyme hyperactivationSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Targeting isocitrate dehydrogenase mutations by enzyme hyperactivationSLOAN-KETTERING INST CAN RESEARCH2024–2029
- Metabolic control of normal and malignant hematopoiesisSLOAN-KETTERING INST CAN RESEARCH2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
